CoChat
Sign Up
Cited by 2,173Photodynamic Therapy Research StudiesNanoplatforms for cancer theranosticsPorphyrin and Phthalocyanine Chemistry

The DOI matches its Crossref record.

Photodynamic therapy – mechanisms, photosensitizers and combinations

Kwiatkowski, Stanisław, Knap, Bartosz, Przystupski, Dawid, Saczko, Jolanta, Kędzierska, Ewa, Knap-Czop, Karolina, Kotlińska, Jolanta, Michel, Olga, Kotowski, Krzysztof, Kulbacka, Julita·2018·Biomedicine & Pharmacotherapy
DOI 10.1016/j.biopha.2018.07.049
Open this paper in CoChat — free account

Abstract

Photodynamic therapy (PDT) is a modern and non-invasive form of therapy, used in the treatment of non-oncological diseases as well as cancers of various types and locations. It is based on the local or systemic application of a photosensitive compound - the photosensitizer, which is accumulated in pathological tissues. The photosensitizer molecules absorb the light of the appropriate wavelength, initiating the activation processes leading to the selective destruction of the inappropriate cells. The photocytotoxic reactions occur only within the pathological tissues, in the area of photosensitizer distribution, enabling selective destruction. Over the last decade, a significant acceleration in the development of nanotechnology has been observed. The combination of photosensitizers with nanomaterials can improve the photodynamic therapy efficiency and eliminate its side effects as well. The use of nanoparticles enables achievement a targeted method which is focused on specific receptors, and, as a result, increases the selectivity of the photodynamic therapy. The object of this review is the anticancer application of PDT, its advantages and possible modifications to potentiate its effects.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2018.07.049

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 82

  1. Luo, 2017, Chemophototherapy: an emerging treatment option for solid tumors, Adv. Sci., 4, 1600106, 10.1002/advs.201600106 · DOI
  2. Kharkwal, 2011, Photodynamic therapy for infections: clinical applications, Lasers Surg. Med., 43, 755, 10.1002/lsm.21080 · DOI
  3. Sperandio, 2013, Antimicrobial photodynamic therapy to kill Gram-negative bacteria, Recent Pat. Antiinfect. Drug Discov., 8, 108, 10.2174/1574891X113089990012 · DOI
  4. Schmitt, 2012, Drug targeting strategies for photodynamic therapy, Anticancer Agents Med. Chem., 12, 500, 10.2174/187152012800617830 · DOI
  5. Allison, 2013, Photodynamic therapy (PDT): PDT mechanisms, Clin. Endosc., 46, 24, 10.5946/ce.2013.46.1.24 · DOI
  6. Robertson, 2009, Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT, J. Photochem. Photobiol. B Biol., 96, 1, 10.1016/j.jphotobiol.2009.04.001 · DOI
  7. Castano, 2005, Mechanisms in photodynamic therapy: part two—cellular signaling, cell metabolism and modes of cell death, Photodiagn. Photodyn. Ther., 2, 1, 10.1016/S1572-1000(05)00030-X · DOI
  8. Nowak-Stepniowska, 2013, [Photodynamic method of cancer diagnosis and therapy--mechanisms and applications], Postepy Biochem., 59, 53
  9. Luksiene, 2003, Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment, Med. (Kaunas), 39, 1137
  10. Juzeniene, 2007, The history of PDT in Norway, Photodiagn. Photodyn. Ther., 4, 3, 10.1016/j.pdpdt.2006.11.002 · DOI
  11. Fonseca, 2006, Triplet-state and singlet oxygen formation in fluorene-based alternating copolymers, J. Phys. Chem. B, 110, 8278, 10.1021/jp060251f · DOI
  12. Kessel, 2010, Photodynamic therapy and cell death pathways, 35, 10.1007/978-1-60761-697-9_3 · DOI
  13. Plaetzer, 2003, The modes of cell death induced by PDT: an overview, Med. Laser Appl., 18, 7, 10.1078/1615-1615-00082 · DOI
  14. Buytaert, 2007, Molecular effectors of multiple cell death pathways initiated by photodynamic therapy, Biochim. Biophys. Acta Rev. Cancer., 1776, 86, 10.1016/j.bbcan.2007.07.001 · DOI
  15. Mehraban, 2015, Developments in PDT sensitizers for increased selectivity and singlet oxygen production, Mater. (Basel Switz.), 8, 4421, 10.3390/ma8074421 · DOI
  16. Vrouenraets, 2003, Basic principles, applications in oncology and improved selectivity of photodynamic therapy, Anticancer Res., 23, 505
  17. Cruz, 2013, The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics, Front. Pharmacol., 4, 119, 10.3389/fphar.2013.00119 · DOI
  18. Hamblin, 1994, Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins, J. Photochem. Photobiol. B., 26, 147, 10.1016/1011-1344(94)07036-9 · DOI
  19. Castano, 2005, Mechanisms in photodynamic therapy: Part three—Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction, Photodiagn. Photodyn. Ther., 2, 91, 10.1016/S1572-1000(05)00060-8 · DOI
  20. Huang, 2008, Photodynamic therapy for treatment of solid tumors--potential and technical challenges, Technol. Cancer Res. Treat., 7, 309, 10.1177/153303460800700405 · DOI
  21. Krammer, 2001, Vascular effects of photodynamic therapy, Anticancer Res., 21, 4271
  22. Reginato, 2014, Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects, World J. Immunol., 4, 1, 10.5411/wji.v4.i1.1 · DOI
  23. Castano, 2006, Photodynamic therapy and anti-tumour immunity, Nat. Rev. Cancer, 6, 535, 10.1038/nrc1894 · DOI
  24. Agostinis, 2011, Photodynamic therapy of cancer: an update, CA Cancer J. Clin., 61, 250, 10.3322/caac.20114 · DOI · Paper page
  25. Kou, 2017, Porphyrin photosensitizers in photodynamic therapy and its applications, Oncotarget, 8, 81591, 10.18632/oncotarget.20189 · DOI
  26. Nyman, 2004, Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy, J. Photochem. Photobiol. B, 73, 1, 10.1016/j.jphotobiol.2003.10.002 · DOI
  27. Fornalski, 2006, Photodynamic therapy mechanism of action and adhibition in dermatology, Nowa Med., 4, 71
  28. Allison, 2010, Oncologic photodynamic therapy photosensitizers: A clinical review, Photodiagn. Photodyn. Ther., 7, 61, 10.1016/j.pdpdt.2010.02.001 · DOI
  29. Taub, 2004, Photodynamic therapy in dermatology: history and horizons, J. Drugs Dermatol., 3, S8
  30. Abrahamse, 2016, New photosensitizers for photodynamic therapy, Biochem. J., 473, 347, 10.1042/BJ20150942 · DOI
  31. Zhang, 2018, An updated overview on the development of new photosensitizers for anticancer photodynamic therapy, Acta Pharm. Sin. B, 8, 137, 10.1016/j.apsb.2017.09.003 · DOI
  32. Chatterjee, 2008, Nanoparticles in photodynamic therapy: an emerging paradigm, Adv. Drug Deliv. Rev., 60, 1627, 10.1016/j.addr.2008.08.003 · DOI
  33. Yoon, 2013, Advance in photosensitizers and light delivery for photodynamic therapy, Clin. Endosc., 46, 7, 10.5946/ce.2013.46.1.7 · DOI
  34. Moriwaki, 2018, Synthesis and photophysical properties of S -Mannosylated chlorins and their effect on photocytotoxicity in HeLa cells, Bull. Chem. Soc. Jpn., 91, 230, 10.1246/bcsj.20170271 · DOI
  35. De Rosa, 2000, Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives, Pharm. Res., 17, 1447, 10.1023/A:1007612905378 · DOI
  36. Morton, 2002, The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments?, J. Dermatol. Treat., 13, s25, 10.1080/095466302317414672 · DOI
  37. Josefsen, 2008, Photodynamic therapy: novel third-generation photosensitizers one step closer?, Br. J. Pharmacol., 154, 1, 10.1038/bjp.2008.98 · DOI
  38. Kataoka, 2017, New photodynamic therapy with next-generation photosensitizers, Ann. Transl. Med., 5, 183, 10.21037/atm.2017.03.59 · DOI
  39. Savellano, 2003, Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates, Photochem. Photobiol., 77, 431, 10.1562/0031-8655(2003)077<0431:TCTOTE>2.0.CO;2 · DOI
  40. Shi, 2017, Cancer nanomedicine: progress, challenges and opportunities, Nat. Rev. Cancer, 17, 20, 10.1038/nrc.2016.108 · DOI · Paper page
  41. Ariga, 2011, Layer-by-layer self-assembled shells for drug delivery, Adv. Drug Deliv. Rev., 63, 762, 10.1016/j.addr.2011.03.016 · DOI
  42. Nakamura, 2017, Significance of optimization of phospholipid poly(Ethylene glycol) quantity for coating carbon nanohorns to achieve low cytotoxicity, Bull. Chem. Soc. Jpn., 90, 662, 10.1246/bcsj.20170003 · DOI
  43. Hamblin, 2015, Nanotechnology for photodynamic therapy: a perspective from the laboratory of Dr. Michael R. Hamblin in the Wellman Center for Photomedicine at Massachusetts General Hospital and Harvard Medical School, Nanotechnol. Rev., 4, 359, 10.1515/ntrev-2015-0027 · DOI
  44. Lee, 2011, Polymeric nanoparticles for photodynamic therapy, 151, 10.1007/978-1-61779-052-2_11 · DOI
  45. Hong, 2016, Targeted and effective photodynamic therapy for cancer using functionalized nanomaterials, Acta Pharm. Sin. B, 6, 297, 10.1016/j.apsb.2016.01.007 · DOI
  46. Hao, 2017, Multifunctional nanoplatform for enhanced photodynamic cancer therapy and magnetic resonance imaging, Colloids Surf. B Biointerfaces, 151, 384, 10.1016/j.colsurfb.2016.10.039 · DOI
  47. Rong, 2014, Photosensitizer Loaded Nano-Graphene for Multimodality Imaging Guided Tumor Photodynamic Therapy, Theranostics, 4, 229, 10.7150/thno.8070 · DOI
  48. Ding, 2011, Photoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia, J. Control. Release, 156, 276, 10.1016/j.jconrel.2011.08.019 · DOI
  49. Avci, 2014, Photodynamic therapy: one step ahead with self-assembled nanoparticles, J. Biomed. Nanotechnol., 10, 1937, 10.1166/jbn.2014.1953 · DOI
  50. Zeisser-Labouèbe, 2006, Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer, Int. J. Pharm., 326, 174, 10.1016/j.ijpharm.2006.07.012 · DOI
  51. Wang, 2011, Novel methods to incorporate photosensitizers into nanocarriers for cancer treatment by photodynamic therapy, Lasers Surg. Med., 43, 686, 10.1002/lsm.21113 · DOI
  52. Qin, 2011, Methylene blue covalently loaded polyacrylamide nanoparticles for enhanced tumor-targeted photodynamic therapy, Photochem. Photobiol. Sci., 10, 832, 10.1039/c1pp05022b · DOI
  53. Tang, 2008, Encapsulation of methylene blue in polyacrylamide nanoparticle platforms protects its photodynamic effectiveness, Biochem. Biophys. Res. Commun., 369, 579, 10.1016/j.bbrc.2008.02.066 · DOI
  54. Kuruppuarachchi, 2011, Polyacrylamide nanoparticles as a delivery system in photodynamic therapy, Mol. Pharm., 8, 920, 10.1021/mp200023y · DOI
  55. Tang, 2005, Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms, Photochem. Photobiol., 81, 242
  56. Kopecek, 2010, HPMA copolymers: origins, early developments, present, and future, Adv. Drug Deliv. Rev., 62, 122, 10.1016/j.addr.2009.10.004 · DOI
  57. Yang, 2015, Gold nanoparticle-enhanced photodynamic therapy: effects of surface charge and mitochondrial targeting, Ther. Deliv., 6, 307, 10.4155/tde.14.115 · DOI
  58. Meyers, 2015, Peptide-targeted gold nanoparticles for photodynamic therapy of brain Cancer, Part. Part. Syst. Charact., 32, 448, 10.1002/ppsc.201400119 · DOI
  59. Xiao, 2011, Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells, ACS Nano, 5, 3651, 10.1021/nn1035262 · DOI
  60. Komiyama, 2017, Chemistry can make strict and fuzzy controls for bio-systems: DNA nanoarchitectonics and cell-macromolecular nanoarchitectonics, Bull. Chem. Soc. Jpn., 90, 967, 10.1246/bcsj.20170156 · DOI
  61. Zhang, 2007, Versatile photosensitizers for photodynamic therapy at infrared excitation, J. Am. Chem. Soc., 129, 4526, 10.1021/ja0700707 · DOI
  62. Choromańska, 2013, Photodynamic therapy – principles, mechanism, clinical applications, Nowa Med., 1, 26
  63. I. Cozzani, G. Jori, G. Bertoloni, C. Milanesi, P. Carlini, T. Sicuro, A. Ruschi, Efficient photosensitization of malignant human cells in vitro by liposome-bound porphyrins., Chem. Biol. Interact. 53 (n.d.) 131–143 http://www.ncbi.nlm.nih.gov/pubmed/3995649. · DOI
  64. Konan, 2002, State of the art in the delivery of photosensitizers for photodynamic therapy, J. Photochem. Photobiol. B, 66, 89, 10.1016/S1011-1344(01)00267-6 · DOI
  65. Paszko, 2011, Nanodrug applications in photodynamic therapy, Photodiagn. Photodyn. Ther., 8, 14, 10.1016/j.pdpdt.2010.12.001 · DOI
  66. Chen, 2005, Liposomal delivery of photosensitising agents, Expert Opin. Drug Deliv., 2, 477, 10.1517/17425247.2.3.477 · DOI
  67. Polo, 2002, Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts, Int. J. Biochem. Cell Biol., 34, 10, 10.1016/S1357-2725(01)00092-9 · DOI
  68. Mazière, 1991, The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours, J. Photochem. Photobiol. B, 8, 351, 10.1016/1011-1344(91)80111-T · DOI
  69. Luiza Andreazza, 2016, Int. J. Pharm., 510, 240, 10.1016/j.ijpharm.2016.06.009 · DOI
  70. Gehl, 2003, Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research, Acta Physiol. Scand., 177, 437, 10.1046/j.1365-201X.2003.01093.x · DOI
  71. Potter, 2003, Transfection by electroporation, Curr. Protoc. Mol. Biol.
  72. Reigada, 2014, Electroporation of heterogeneous lipid membranes, Biochim. Biophys. Acta - Biomembr., 1838, 814, 10.1016/j.bbamem.2013.10.008 · DOI
  73. Cadossi, 2014, Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy, Future Oncol., 10, 877, 10.2217/fon.13.235 · DOI
  74. Labanauskiene, 2009, Enhancement of photodynamic tumor therapy effectiveness by electroporation in vitro, Med. (Kaunas), 45, 372
  75. Kulbacka, 2011, The influence of electroporation on in vitro photodynamic therapy of human breast carcinoma cells, Folia Biol. (Praha), 57, 112, 10.14712/fb2011057030112 · DOI
  76. Kulbacka, 2015, Nanosecond pulsed electric fields (nsPEFs) impact and enhanced Photofrin II® delivery in photodynamic reaction in cancer and normal cells, Photodiagn. Photodyn. Ther., 12, 621, 10.1016/j.pdpdt.2015.11.002 · DOI
  77. Wezgowiec, 2013, Electric field-assisted delivery of photofrin to human breast carcinoma cells, J. Membr. Biol., 246, 725, 10.1007/s00232-013-9533-z · DOI
  78. Choromanska, 2015, Effects of electrophotodynamic therapy in vitro on human melanoma cells – melanotic (MeWo) and amelanotic (C32), Melanoma Res., 25, 210, 10.1097/CMR.0000000000000153 · DOI
  79. Kulbacka, 2016, Electroporation and lipid nanoparticles with cyanine IR-780 and flavonoids as efficient vectors to enhanced drug delivery in colon cancer, Bioelectrochemistry, 110, 19, 10.1016/j.bioelechem.2016.02.013 · DOI
  80. Zielichowska, 2015, The photodynamic effect of far-red range phthalocyanines (AlPc and Pc green) supported by electropermeabilization in human gastric adenocarcinoma cells of sensitive and resistant type, Biomed. Pharmacother., 69, 145, 10.1016/j.biopha.2014.11.017 · DOI
  81. Weżgowiec, 2018, Biological effects in photodynamic treatment combined with electropermeabilization in wild and drug resistant breast cancer cells, Bioelectrochemistry, 123, 9, 10.1016/j.bioelechem.2018.04.008 · DOI
  82. Wallace, 2009, Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults, Mol. Ther., 17, 922, 10.1038/mt.2009.27 · DOI

Cited by

Sorted by citations

Items 601–700 of 1,000

Metadata

Authors
Kwiatkowski, S., Knap, B., Przystupski, D., Saczko, J., Kędzierska, E., Knap-Czop, K., Kotlińska, J., Michel, O., Kotowski, K., & Kulbacka, J.
Affiliations
  • Wroclaw Medical University (PL)
  • Medical University of Lublin (PL)
Corresponding author
Kulbacka, Julita
ORCID
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2018-10
Volume
106
Pages
1098-1107
ISSN
0753-3322 (ISSN-L)
DOI
10.1016/j.biopha.2018.07.049
OpenAlex
W2884145325
Cited by
2,173
References
0
Citations by year
2026: 192 · 2025: 360 · 2024: 404 · 2023: 362 · 2022: 340 · 2021: 272 · 2020: 174 · 2019: 61 · 2018: 7
FWCI
22.96
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Biomedicine & Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu
  • Uniwersytet Medyczny w Lublinie
  • Servier
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Materials Chemistry › Porphyrin and Phthalocyanine Chemistry
Keywords
photodynamic therapy, photosensitizers, photocytotoxicity, targeted drug delivery, nanoparticles, nanomaterials, combination therapy
MeSH terms
Animals, Drug Carriers, Humans, Neoplasms, Photochemotherapy, Drug Delivery Systems, Photosensitizing Agents, Nanomedicine, Electrochemotherapy, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review